drugset / Trial / NCT02436668
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Timeline
- Start
- 2015-05
- Primary completion
- 2018-10
- Completion
- 2019-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ibrutinib | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |